Gene · 10683
Papers2,335
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,335
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Notch Signaling Exacerbates Pulmonary Fibrosis by Regulating the Differentiation of CD4+ Tissue-Resident Memory T Cells. | Biomolecules | 2026 | 41750395 | PubTator, text mining | PubMed |
| Evolution of Immune Checkpoint Blockade in Metastatic NSCLC: A Narrative Review of Emerging Bispecific Antibodies and the Practical Challenges of Clinical Integration. | Cancers (Basel) | 2026 | 41749962 | PubTator, text mining | PubMed |
| Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies. | Curr Oncol | 2026 | 41744848 | PubTator, text mining | PubMed |
| Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer. | Biology (Basel) | 2026 | 41744665 | PubTator, text mining | PubMed |
| Molecular mechanisms and classification of castration-resistant prostate cancer: Insights into androgen receptor, cancer stem cells, and neuroendocrine features. | Curr Urol | 2026 | 41743916 | PubTator, text mining | PubMed |
| Cell-surface targets for prostate cancer therapeutics. | Urol Oncol | 2026 | 41741268 | PubTator, text mining | PubMed |
| Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists. | Oncologist | 2026 | 41739670 | PubTator, text mining | PubMed |
| Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer. | J Natl Cancer Cent | 2026 | 41738039 | PubTator, text mining | PubMed |
| Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis. | Nat Commun | 2026 | 41735293 | PubTator, text mining | PubMed |
| The path forward for T cell engagers in patients with prostate cancer. | J Immunother Cancer | 2026 | 41734994 | PubTator, text mining | PubMed |
| The role of antibody-drug conjugates in the treatment of lung cancer. | Front Oncol | 2026 | 41727667 | PubTator, text mining | PubMed |
| Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology. | bioRxiv | 2026 | 41726945 | PubTator, text mining | PubMed |
| Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics. | Oncoimmunology | 2026 | 41700001 | PubTator, text mining | PubMed |
| Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review. | Clin Lung Cancer | 2026 | 41653583 | PubTator, text mining | PubMed |
| Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy. | Med Oncol | 2026 | 41653365 | PubTator, text mining | PubMed |
| Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers. | Proc Natl Acad Sci U S A | 2026 | 41628333 | PubTator, text mining | PubMed |
| Flare Reaction following Tarlatamab Treatment in a Patient with Extensive-Stage Small Cell Lung Cancer: Case Report. | Case Rep Oncol | 2026 | 41626599 | PubTator, text mining | PubMed |
| Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugates. | Cancer Treat Rev | 2026 | 41604872 | PubTator, text mining | PubMed |
| Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors. | Gynecol Oncol | 2026 | 41576550 | PubTator, text mining | PubMed |
| From Simple Scores to Intelligent Systems: Encouraging the Development, Validation and Adoption of Robust Prognostic Tools in Small Cell Lung Cancer. | Technol Cancer Res Treat | 2026 | 41575930 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10683/papers?page=7